NDA 021398 · Abbvie
Combigan
Brimonidine Tartrate, Timolol Maleate · Ophthalmic
Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Oct 30, 2007
Approved uses
1
Original approval plus efficacy supplements
Registered trials
177
44 Phase 3, 5 recruiting
FAERS reports
6,644
2,704 serious, 318 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 17, 2026.
COMBIGAN ® is indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP. The IOP-lowering of COMBIGAN dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day. COMBIGAN is a combination of brimonidine tartrate, an alpha-adrenergic receptor agonist, and timolol maleate, a beta-adrenergic receptor inhibitor, indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP. The IOP-lowering of COMBIGAN dosed twice a day was slightly less than that seen with the concomitant administration of timolol maleate ophthalmic solution, 0.5% dosed twice a day and brimonidine tartrate ophthalmic solution, 0.2% dosed three times per day. ( 1 )
Mechanism: COMBIGAN is comprised of two components: brimonidine tartrate and timolol. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic nerve damage. COMBIGAN is a relatively selective alpha-2 adrenergic receptor agonist with a non-selective beta-adrenergic receptor inhibitor. Both brimonidine and timolol...
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 30, 2007 Original approval · Type 4 - New Combination ReviewPediatric Medical ReviewPediatric Clinical Pharmacology Review
1 products under this application
- COMBIGAN · BRIMONIDINE TARTRATE 0.2%; TIMOLOL MALEATE EQ 0.5% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Brimonidine" as an intervention, any sponsor and status, largest first.
- Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Alcon ResearchIndustry
NCT01309204 · 1,184 participants · Start May 2011 · Primary completion Jan 2013
Drug: Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension; Vehicle and 2 more · For: Open-Angle Glaucoma; Ocular Hypertension
- Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%Pivotal-lookingCompleted
Alcon ResearchIndustry
NCT01297920 · 1,062 participants · Start Mar 2011 · Primary completion Jun 2012
Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide ophthalmic suspension, 1% and 1 more · For: Open-Angle Glaucoma; Ocular Hypertension
- Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%Pivotal-lookingCompleted
Alcon ResearchIndustry
NCT01297517 · 1,001 participants · Start Feb 2011 · Primary completion Mar 2012
Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide ophthalmic suspension, 1% and 1 more · For: Open-Angle Glaucoma; Ocular Hypertension
- Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Alcon ResearchIndustry
NCT01310777 · 771 participants · Start May 2011 · Primary completion Jan 2013
Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide 1% ophthalmic suspension and 1 more · For: Open-Angle Glaucoma; Ocular Hypertension
- Evaluation of Safety and Efficacy of PDP-716Pivotal-lookingCompleted
Sun Pharma Advanced Research Company LimitedIndustry
NCT03450629 · 682 participants · Start Sep 13, 2018 · Primary completion Dec 1, 2020
Drug: Brimonidine Tartrate Ophthalmic Suspension; Brimonidine Tartrate Ophthalmic Solution · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Chandler, Arizona; Prescott, Arizona; Sun City, Arizona · 47 sites in all
- Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic PresbyopiaPivotal-lookingCompleted
Visus TherapeuticsAcademic, hospital or other
NCT05135286 · 629 participants · Start Mar 15, 2022 · Primary completion Mar 13, 2025
Drug: BRIMOCHOL™ PF; Carbachol PF and 1 more · For: Presbyopia
Sites: Chandler, Arizona; Phoenix, Arizona; Sun City, Arizona · 42 sites in all
- Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension PatientsPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT00651612 · 604 participants · Start Nov 2005 · Primary completion Jan 2007
Drug: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution; Concurrent brimonidine 0.2% and 0.5% timolol · For: Glaucoma; Ocular Hypertension
Sites: Newport Beach, California
- Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular HypertensionPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT00332436 · 586 participants · Start Dec 1999 · Primary completion Nov 2001
Drug: brimonidine/timolol fixed combination · For: Ocular Hypertension
Sites: Louisville, Kentucky
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- ocular hyperaemia544
- eye irritation532
- eye pain481
- fatigue383
- drug ineffective365
- vision blurred341
- off label use297
- intraocular pressure increased295
- dizziness270
- eye pruritus255
- headache246
- diarrhoea215
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 13 |
| 2008 | 40 |
| 2009 | 338 |
| 2010 | 193 |
| 2011 | 224 |
| 2012 | 158 |
| 2013 | 181 |
| 2014 | 213 |
| 2015 | 479 |
| 2016 | 695 |
| 2017 | 602 |
| 2018 | 611 |
| 2019 | 555 |
| 2020 | 561 |
| 2021 | 453 |
| 2022 | 369 |
| 2023 | 305 |
| 2024 | 257 |
| 2025 | 266 |
| 2026 | 128 |
Recalls
2 FDA enforcement reports for this application.
Mar 19, 2019 · Class II · Terminated
cGMP Deviations
Oct 19, 2017 · Class III · Terminated
Failed Impurities/Degradation Specifications.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Combigan (Brimonidine Tartrate/Timolol)
2024 spending
$162M
Beneficiaries
114,398
465,280 claims
Per beneficiary
$1,418
$38.75 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $379,353,449 |
| 2021 | $392,681,109 |
| 2022 | $291,993,108 |
| 2023 | $232,102,953 |
| 2024 | $162,254,896 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Post-acne erythema treatment: A systematic review of the literature.
Kalantari Y, Dadkhahfar S, Etesami I · J Cosmet Dermatol 2022 · Systematic Review
- Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, et al. · Ophthalmology 2016 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Efficacy of Widely Used Topical Drugs for Rosacea: A Systematic Review and Meta-Analysis.
Gao X, Xiang W · Actas Dermosifiliogr 2025 · Systematic Review, Meta-Analysis
- Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments.
van Zuuren EJ, Fedorowicz Z, Tan J, et al. · Br J Dermatol 2019 · Systematic Review
- Interventions for rosacea.
van Zuuren EJ, Fedorowicz Z, Carter B, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Neuroprotection for treatment of glaucoma in adults.
Sena DF, Lindsley K · Cochrane Database Syst Rev 2017 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.